![Haru Morita](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Haru Morita
Chief Executive Officer at
MODALIS THERAPEUTICS CORPORATION
Net worth: 923 744 $ as of 2026-10-30
Profile
Mr. Haru Morita is a Chief Executive Officer at Modalis Therapeutics, Inc. and a Chief Executive Officer & Representative Director at Modalis Therapeutics Corp.
He is on the Board of Directors at Modalis Therapeutics Corp.
Mr. Morita was previously employed as a Chairman, President & Chief Executive Officer by REGiMMUNE Corp., a Principal by Booz Allen Hamilton International (U.K.) Ltd., a Research Scientist by Kirin Brewery Co. Ltd., and a Director-Business Development by Y's Therapeutics, Inc. He received his undergraduate degree from School of Engineering, The University of Tokyo and a graduate degree from School of Engineering, The University of Tokyo.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-05-26 | 5,195,700 ( 4.57% ) | 923 744 $ | 2026-10-30 |
Haru Morita active positions
| Companies | Position | Start |
|---|---|---|
| MODALIS THERAPEUTICS CORPORATION | Chief Executive Officer | 2015-12-31 |
Modalis Therapeutics, Inc.
 Modalis Therapeutics, Inc. Aerospace & DefenseElectronic Technology Part of Modalis Therapeutics Corp., Modalis Therapeutics, Inc. is an American biotechnology company specializing in gene therapies for rare genetic diseases. The company is located in the US. The company develops treatments using its proprietary CRISPR-GNDM® platform, an epigenome editing technology that modulates gene regulatory regions to correct gene regulation errors without altering DNA sequences. Its approach targets severe disorders affecting muscles, the heart, and the central nervous system. Modalis employs a hybrid business model that combines in-house drug development with collaborative partnerships, advancing candidates through discovery and early clinical stages before licensing manufacturing and commercialization rights. The company focuses on diseases with high unmet medical needs, including muscular dystrophies, cardiomyopathies, neurodegenerative diseases, and severe pediatric epilepsy, and its pipeline includes gene therapy candidates for conditions such as LAMA2-related congenital muscular dystrophy, Duchenne muscular dystrophy, myotonic dystrophy type 1, facioscapulohumeral muscular dystrophy, dilated cardiomyopathy, tauopathies, Angelman syndrome, and Dravet syndrome. Modalis utilizes muscle-specific viral vectors and delivery technologies to enhance targeting and safety, and actively seeks partnerships to expand and optimize its therapeutic pipeline. Haru Morita has been the CEO of the company since 2016. | Chief Executive Officer | 2016-03-31 |
Former positions of Haru Morita
| Companies | Position | End |
|---|---|---|
Booz Allen Hamilton International (U.K.) Ltd.
 Booz Allen Hamilton International (U.K.) Ltd. Miscellaneous Commercial ServicesCommercial Services Provides management and technology consulting services | Corporate Officer/Principal | - |
Kirin Brewery Co. Ltd.
 Kirin Brewery Co. Ltd. Beverages: AlcoholicConsumer Non-Durables Manufactures beer | Chief Tech/Sci/R&D Officer | - |
Y's Therapeutics, Inc.
 Y's Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceuticals | Corporate Officer/Principal | - |
REGiMMUNE Corp.
 REGiMMUNE Corp. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops immune medicines | Chief Executive Officer | - |
Education of Haru Morita
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
7
1st degree connections
7
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 7 |
|---|---|
Y's Therapeutics, Inc.
Y's Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceuticals | Health Technology |
Kirin Brewery Co. Ltd.
Kirin Brewery Co. Ltd. Beverages: AlcoholicConsumer Non-Durables Manufactures beer | Consumer Non-Durables |
REGiMMUNE Corp.
REGiMMUNE Corp. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops immune medicines | Health Technology |
Booz Allen Hamilton International (U.K.) Ltd.
Booz Allen Hamilton International (U.K.) Ltd. Miscellaneous Commercial ServicesCommercial Services Provides management and technology consulting services | Commercial Services |
School of Engineering, The University of Tokyo
 School of Engineering, The University of Tokyo Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Modalis Therapeutics Corp.
 Modalis Therapeutics Corp. BiotechnologyHealth Technology Develops transformative therapeutics for diseases which are caused by malfunctioning of genes | Health Technology |
Modalis Therapeutics, Inc.
Modalis Therapeutics, Inc. Aerospace & DefenseElectronic Technology Part of Modalis Therapeutics Corp., Modalis Therapeutics, Inc. is an American biotechnology company specializing in gene therapies for rare genetic diseases. The company is located in the US. The company develops treatments using its proprietary CRISPR-GNDM® platform, an epigenome editing technology that modulates gene regulatory regions to correct gene regulation errors without altering DNA sequences. Its approach targets severe disorders affecting muscles, the heart, and the central nervous system. Modalis employs a hybrid business model that combines in-house drug development with collaborative partnerships, advancing candidates through discovery and early clinical stages before licensing manufacturing and commercialization rights. The company focuses on diseases with high unmet medical needs, including muscular dystrophies, cardiomyopathies, neurodegenerative diseases, and severe pediatric epilepsy, and its pipeline includes gene therapy candidates for conditions such as LAMA2-related congenital muscular dystrophy, Duchenne muscular dystrophy, myotonic dystrophy type 1, facioscapulohumeral muscular dystrophy, dilated cardiomyopathy, tauopathies, Angelman syndrome, and Dravet syndrome. Modalis utilizes muscle-specific viral vectors and delivery technologies to enhance targeting and safety, and actively seeks partnerships to expand and optimize its therapeutic pipeline. Haru Morita has been the CEO of the company since 2016. | Electronic Technology |
- Stock Market
- Insiders
- Haru Morita
